Digital Health Monthly: Scientific Webinar Series
Overcoming Treatment Barriers: How DHTs can Facilitate Widespread Outpatient Immunotherapy Treatments
Tuesday, May 27, 2025 @ 12 PM ET
Upcoming Digital Health Monthly:
Scientific Webinar Series
Accelerating DHT Research and Drug Development with Open-Source Big Data from Population Studies
Tuesday, December 3 @ 12 PM ET
Digital Health Monthly: Scientific Webinar Series
Sensor-based DHTs are shedding an illuminating light on how people function in their real-world environments. Drug developers, researchers, patients, and regulators are realizing the multifaceted value sensor-based DHTs can bring to clinical research.
As their adoption continues to grow, the ActiGraph team is excited to continue ‘Digital Health Monthly’, a monthly series of science-focused webinars to share the latest high-impact developments in clinical research from innovators in the digital health field. Each month, we feature brief data-driven presentations from clinical researchers, data scientists, and biostatisticians on a focused topic with dedicated time for audience Q&A. We believe that together, we can move the digital health technology field forward faster, and we are excited for this opportunity to facilitate important discussions on the latest research with members of the digital health community.
Immunotherapies, such as CAR-T cell therapies and T-Cell Engager therapies, have shown clinical benefit in multiple cancers for patients who previously would have exhausted treatment options. Though these immunotherapies can be lifesaving and offer hope to patients when there previously was none, they have associated risks that can limit access, complicate treatment, and slow development. To realize the full potential of immunotherapies in cancer care, it’s important to fully understand and address the challenges of delivering these types of therapies to optimize development and expand patient access.
In this session of Digital Health Monthly, we’ll review the risk of immunotherapy-related adverse events, like cytokine release syndrome (CRS), and examine how this introduces complexities in treatment development and delivery from the perspectives of patients, clinicians, and drug developers.
Our expert panel will share how digital health technologies can enable remote monitoring to detect early signs of CRS, addressing key challenges that limit patient access while preserving patient safety. They’ll share data on the technical feasibility from the deployment of DHTs in immunotherapy trials, outline key lessons learned, and discuss next steps to fully realize a CRS monitoring digital health solution.
What you'll learn:
- Challenges in immunotherapy treatment resulting from the risk of adverse events like CRS
- How digital health technology can enable remote monitoring and early detection of CRS following immunotherapy treatment
- How high-fidelity, high-frequency data provides the type of information needed to develop robust CRS monitoring solutions
- What steps the industry is taking next to fully realize the potential of CRS monitoring with DHTs
Speakers
